Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (126)	1/9/1998 1:28:00 AM
From: Asymmetric	Read Replies (1) \| Respond to of 258

I feel safer on the sidelines. From what I can see the market rotation right now is out of smaller cap, riskier stocks into defensive issues like utilities and consumer stuff. So I don't expect Martek to make much headway given general market trends. The other two things I'd want to see is 1) Martek showing me the money - that is that they can start turning a profit and can do so consistently. 2) Mutual fund money flows would have to remain heavily on the positive side. To me Martek is a trickle down stock. Throw enough money at the market and some of it will reach down to where Martek is. If fund flows slow like I think they will this year, or even heaven forbid, start to show outflow then Martek will at best be marking time throughout the year. Good luck.

To: Machaon who wrote (126)	2/20/1998 2:41:00 PM
From: Machaon	Respond to of 258

New Patent Issued to Martek Protecting Lower Cost DHA COLUMBIA, Md.--(BUSINESS WIRE)--Feb. 2, 1998--Martek Biosciences Corp. (NASDAQ: MATK - news) today announced that the U.S. Patent and Trademark Office has issued patent number 5,711,983 to the company covering the composition of matter of its DHA-rich algal biomass. Martek's algal biomass is the material from which the company derives its DHA oil. ''This patent is important because it protects an inexpensive source of DHA. Instead of processing Martek's DHA-rich algal biomass into DHA-rich oil, the biomass has the potential to be ingested directly by humans, commercial meat and egg producing animals, and fish,'' said Henry Linsert, Jr., Martek's chairman and CEO. This press release contains forward-looking statements regarding the protection afforded by Martek's patents. Such statements involve risks and uncertainties that could cause actual results to differ due to a variety of risk factors set forth from time to time in the company's filings with the Securities and Exchange Commission, including but not limited to its filed reports on Form 10-K, Form 10-Q and its Form S-3 declared effective on Sept. 26, 1995. Martek Biosciences Corp. develops, manufactures and sells products from microalgae. The company's products include: (1) specialty, edible oils for infant formula, nutritional supplements and foods which play a central role in the development of the eyes and central nervous system; (2) high value reagents to visualize molecular interactions for drug discovery and development and; (3) new, powerful fluorescent markers for diagnostics, rapid, miniaturized screening, and gene and protein detection. Contact: Martek Biosciences Corp. Steve Dubin, chief financial officer or Gregg Lampf, corporate communications 410/740-0081

To: Machaon who wrote (126)	2/20/1998 2:43:00 PM
From: Machaon	Read Replies (1) \| Respond to of 258

Intergen(R) Company to Market Martek's Fluorescent Proteins PURCHASE, N.Y., Feb. 3 /PRNewswire/ -- Intergen(R) Company today announced that as of January 30, 1998 it has entered into an agreement with Martek Biosciences Corporation [Nasdaq:MATK - news] in which Intergen will be the exclusive marketer and distributor of Martek's fluorescent phycobiliproteins and conjugates. These phycobiliproteins are individual algal proteins that have a fluorescent power of up to 1O times that of fluorescein, the most common fluorescent marker. Many of these proteins have the added advantage of being one fifth the size of phycobiliproteins, which should allow researchers to examine intracellular events. The products have been designed for use in a wide array of diagnostic and research applications including immunodiagnostics, flow cytometry, genetic testing, immunofluorescence and imaging technologies. Mr. Robert Beckman, President and CEO of Intergen Company, said, ''Intergen expects these exciting molecules to find many new applications in diagnostics and biotechnology, particularly in the search for active compounds in the pharmaceutical industry.'' ''This arrangement with Intergen marks Martek's formal entry into the market for fluorescent markers,'' said Henry ''Pete'' Linsert, Jr., Martek's Chairman and CEO. ''The research community is seeking alternatives to current radioactive markers, the complexity of chemiluminescence, and dimmer fluorescent markers. These initial products along with soon to be introduced proprietary fluorescent marker products should address those needs.'' Intergen is a leading manufacturer of products that are critical to the commercial development of life sciences into biopharmaceuticals and diagnostics. The company was founded in 1987 and has developed a significant market presence through the international commercialization of its products and through strategic acquisitions. Intergen products are found as components of a wide variety of innovative biotechnology drugs and diagnostics ranging from cancer therapeutics to cardiovascular drugs and immunoassays for infectious diseases. Through its focus on life sciences, the company is a vital partner to its biotechnology customers in providing keys to the development and manufacture of innovative products. Headquartered in Purchase, New York, Intergen maintains global operations with facilities in the United States, Canada and the United Kingdom as well as partnerships in Japan. SOURCE: Intergen Company